Market Cap 71.54M
Revenue (ttm) 24.38M
Net Income (ttm) -53.95M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -221.29%
Debt to Equity Ratio -0.67
Volume 26,400
Avg Vol 32,334
Day's Range N/A - N/A
Shares Out 41.12M
Stochastic %K 8%
Beta 0.86
Analysts Strong Sell
Price Target $7.50

Company Profile

Elutia Inc., a commercial-stage company, develops and commercializes drug-eluting biologics products for neurostimulation and breast reconstruction in the United States. It operates in three segments: Device Protection, Women's Health, and Cardiovascular. The company offers EluPro, which is used to accommodate cardiac implantable electronic devices, such as pacemakers and internal defibrillators; and CanGaroo, which mitigates complications derived from implantable electronic devices and shortcom...

Industry: Medical Devices
Sector: Healthcare
Phone: 240 247 1170
Fax: 408 734 2629
Website: elutia.com
Address:
12510 Prosperity Drive, Suite 370, Silver Spring, United States
Greenpa
Greenpa Jun. 11 at 6:44 PM
$ELUT Tried to get some clarity from IR on reimbursement and potentially need for cash raise by year end. Other questions too. Reached out twice. Either not willing to interact with retail investors or simply not in a position to satisfactorily address concerns. I’m betting they would answer the same questions from a fund. Conceptually intriguing but lots of questions that management should address with investors and publicly.
1 · Reply
Greenpa
Greenpa Jun. 7 at 11:39 PM
$ELUT I think I’m reading the Q&A correctly from Q1 to be that will chew up about $8M of the remaining $17M of cash after q2. It will then drop to $4 or $5 million which means it will have depleted its cash sometime in q4 and be doing another capital raise presumably less than one yearly after last raise. Notably, company is not forecasting a great uptick in EluPro revenue later this year. The CEOs hype doesn’t align well of what the CFO suggests in the Q1 call about cash burn rate.
0 · Reply
Greenpa
Greenpa Jun. 5 at 8:29 PM
$ELUT Not surprised. Cash burn in heavier than appears as earnings are overstated. Reported eps and analyst estimates back out all the heavy litigation costs. That masks the heavy heavy cash burn. Really need big uptick in sales way beyond q1 reported growth given gross margins in 40s. Worth watching to see if litigation gets cleaned up and if sales or margins can significantly increase. Management is unwilling to give meaningful guidance
0 · Reply
Greenpa
Greenpa Jun. 2 at 2:08 AM
$ELUT Upcoming quarterly results will be interesting in terms of whether Boston Scientific can stimulate the sales needed to cut the cash burn meaningfully. I would expect should help.
0 · Reply
Motohead125
Motohead125 May. 31 at 1:01 AM
$ELUT now sell the damn product. This needs to be pulling 100m a yr if it is such a disruptive product.
1 · Reply
DARKP00L
DARKP00L May. 28 at 12:24 PM
$ELUT 08:20 on May. 28 2025 Elutia Publishes Peer-Reviewed Article Describing First Validated Method For Measuring Antibiotic Release From Biologic Envelope #tradeideas
0 · Reply
Thestocktraderhubzee
Thestocktraderhubzee May. 28 at 12:24 PM
$ELUT Elutia Publishes Peer-Reviewed Article Describing First Validated Method For Measuring Antibiotic Release From Biologic Envelope
0 · Reply
JarvisFlow
JarvisFlow May. 9 at 3:01 PM
Lake Street updates rating for Elutia ( $ELUT ) to Buy, target set at 10 → 8.
0 · Reply
PenkeTrading
PenkeTrading May. 6 at 8:26 AM
I found you a Three Black Crows Candle Pattern on the daily chart of Elutia Inc.. $ELUT #Elutia #ThreeBlackCrows #NASDAQ
0 · Reply
DonCorleone77
DonCorleone77 Apr. 21 at 12:22 PM
$ELUT Elutia initiates EluPro clinical study to collect real-world outcome data Elutia announced the initiation of an EluPro clinical study designed to collect patient outcome data in real-world clinical practice. EluPro, the first and only FDA-cleared antibiotic-eluting bioenvelope designed for use with cardiac implantable electronic devices and neurostimulators, was commercially launched earlier this year. The first patient was enrolled at UC San Diego Health. "Every innovation we pursue is driven by a commitment to improving patient care," said Kimberly Mulligan, PhD, Vice President and General Manager of Cardiovascular at Elutia. "With EluPro, we combined trusted antibiotics with a soft, regenerative biomatrix to protect the implant, facilitate implantation, and support healing. This study will allow us to collect data on these differentiating characteristics in real-world practice."
0 · Reply
Latest News on ELUT
Elutia Inc. (ELUT) Q1 2025 Earnings Call Transcript

May 11, 2025, 7:32 AM EDT - 6 weeks ago

Elutia Inc. (ELUT) Q1 2025 Earnings Call Transcript


Elutia Confirms No Material Impact from Global Tariffs

Apr 14, 2025, 8:00 AM EDT - 2 months ago

Elutia Confirms No Material Impact from Global Tariffs


Elutia to Participate in Upcoming Investor Conferences

Apr 3, 2025, 8:00 AM EDT - 2 months ago

Elutia to Participate in Upcoming Investor Conferences


Elutia Inc. (ELUT) Q4 2024 Earnings Call Transcript

Mar 6, 2025, 6:22 PM EST - 3 months ago

Elutia Inc. (ELUT) Q4 2024 Earnings Call Transcript


Elutia Announces $15.0 Million Registered Direct Offering

Feb 3, 2025, 6:30 AM EST - 5 months ago

Elutia Announces $15.0 Million Registered Direct Offering


Elutia Inc. (ELUT) Q3 2024 Earnings Call Transcript

Nov 14, 2024, 8:11 PM EST - 7 months ago

Elutia Inc. (ELUT) Q3 2024 Earnings Call Transcript


Elutia Celebrates First Year

Sep 6, 2024, 4:23 PM EDT - 10 months ago

Elutia Celebrates First Year


Elutia Inc. (ELUT) Q2 2024 Earnings Call Transcript

Aug 10, 2024, 7:27 AM EDT - 11 months ago

Elutia Inc. (ELUT) Q2 2024 Earnings Call Transcript


Elutia Announces $13.26 Million Registered Direct Offering

Jun 17, 2024, 8:01 AM EDT - 1 year ago

Elutia Announces $13.26 Million Registered Direct Offering


Elutia, Inc. (ELUT) Q1 2024 Earnings Call Transcript

May 12, 2024, 12:21 PM EDT - 1 year ago

Elutia, Inc. (ELUT) Q1 2024 Earnings Call Transcript


Elutia, Inc. (ELUT) Q4 2023 Earnings Call Transcript

Mar 7, 2024, 8:43 PM EST - 1 year ago

Elutia, Inc. (ELUT) Q4 2023 Earnings Call Transcript


Elutia Regains Compliance with Nasdaq Listing Requirements

Jan 10, 2024, 4:05 PM EST - 1 year ago

Elutia Regains Compliance with Nasdaq Listing Requirements


Elutia, Inc. (ELUT) Q3 2023 Earnings Call Transcript

Nov 17, 2023, 12:30 PM EST - 1 year ago

Elutia, Inc. (ELUT) Q3 2023 Earnings Call Transcript


Aziyo Biologics, Inc. (AZYO) Q2 2023 Earnings Call Transcript

Aug 20, 2023, 12:41 PM EDT - 2 years ago

Aziyo Biologics, Inc. (AZYO) Q2 2023 Earnings Call Transcript


Aziyo Biologics, Inc. (AZYO) Q1 2023 Earnings Call Transcript

May 14, 2023, 9:32 PM EDT - 2 years ago

Aziyo Biologics, Inc. (AZYO) Q1 2023 Earnings Call Transcript


Greenpa
Greenpa Jun. 11 at 6:44 PM
$ELUT Tried to get some clarity from IR on reimbursement and potentially need for cash raise by year end. Other questions too. Reached out twice. Either not willing to interact with retail investors or simply not in a position to satisfactorily address concerns. I’m betting they would answer the same questions from a fund. Conceptually intriguing but lots of questions that management should address with investors and publicly.
1 · Reply
Greenpa
Greenpa Jun. 7 at 11:39 PM
$ELUT I think I’m reading the Q&A correctly from Q1 to be that will chew up about $8M of the remaining $17M of cash after q2. It will then drop to $4 or $5 million which means it will have depleted its cash sometime in q4 and be doing another capital raise presumably less than one yearly after last raise. Notably, company is not forecasting a great uptick in EluPro revenue later this year. The CEOs hype doesn’t align well of what the CFO suggests in the Q1 call about cash burn rate.
0 · Reply
Greenpa
Greenpa Jun. 5 at 8:29 PM
$ELUT Not surprised. Cash burn in heavier than appears as earnings are overstated. Reported eps and analyst estimates back out all the heavy litigation costs. That masks the heavy heavy cash burn. Really need big uptick in sales way beyond q1 reported growth given gross margins in 40s. Worth watching to see if litigation gets cleaned up and if sales or margins can significantly increase. Management is unwilling to give meaningful guidance
0 · Reply
Greenpa
Greenpa Jun. 2 at 2:08 AM
$ELUT Upcoming quarterly results will be interesting in terms of whether Boston Scientific can stimulate the sales needed to cut the cash burn meaningfully. I would expect should help.
0 · Reply
Motohead125
Motohead125 May. 31 at 1:01 AM
$ELUT now sell the damn product. This needs to be pulling 100m a yr if it is such a disruptive product.
1 · Reply
DARKP00L
DARKP00L May. 28 at 12:24 PM
$ELUT 08:20 on May. 28 2025 Elutia Publishes Peer-Reviewed Article Describing First Validated Method For Measuring Antibiotic Release From Biologic Envelope #tradeideas
0 · Reply
Thestocktraderhubzee
Thestocktraderhubzee May. 28 at 12:24 PM
$ELUT Elutia Publishes Peer-Reviewed Article Describing First Validated Method For Measuring Antibiotic Release From Biologic Envelope
0 · Reply
JarvisFlow
JarvisFlow May. 9 at 3:01 PM
Lake Street updates rating for Elutia ( $ELUT ) to Buy, target set at 10 → 8.
0 · Reply
PenkeTrading
PenkeTrading May. 6 at 8:26 AM
I found you a Three Black Crows Candle Pattern on the daily chart of Elutia Inc.. $ELUT #Elutia #ThreeBlackCrows #NASDAQ
0 · Reply
DonCorleone77
DonCorleone77 Apr. 21 at 12:22 PM
$ELUT Elutia initiates EluPro clinical study to collect real-world outcome data Elutia announced the initiation of an EluPro clinical study designed to collect patient outcome data in real-world clinical practice. EluPro, the first and only FDA-cleared antibiotic-eluting bioenvelope designed for use with cardiac implantable electronic devices and neurostimulators, was commercially launched earlier this year. The first patient was enrolled at UC San Diego Health. "Every innovation we pursue is driven by a commitment to improving patient care," said Kimberly Mulligan, PhD, Vice President and General Manager of Cardiovascular at Elutia. "With EluPro, we combined trusted antibiotics with a soft, regenerative biomatrix to protect the implant, facilitate implantation, and support healing. This study will allow us to collect data on these differentiating characteristics in real-world practice."
0 · Reply
GraceMadam
GraceMadam Apr. 14 at 4:49 PM
$ELUT 🤫NASDAQ:МYNZ — Not Just Another Biotech. It’s Moving. While most chase noise, Маіnz Віоmеd keeps building around mRNA, diagnostics, and early cancer detection — the exact space biotech money’s targeting. 📈 Trading above $3.37 now — volume steady, float tight, no PR yet. Still underexposed. Still early. But that window’s narrowing. 🧪 Microfloat. U.S.-based. Fits every biotech funding screen out there. This isn’t just a sleeper — it’s a setup. The chart’s tightening. The story’s strong. One headline, and it’s gone. 📊 I’m not watching from the sidelines — I’m already positioned. Let’s see how this plays out. Could move fast. DYOR. But maybe do it before this wakes up for real.
0 · Reply
NVDAMillionaire
NVDAMillionaire Mar. 26 at 4:23 PM
$ELUT EluPro launch looking promising. Device protection segment showing real potential. Might nibble here as FDA clearance and early adoption signal strong market entry. Watching how Boston Scientific partnership develops in Q1. thoughtful article: https://beyondspx.com/article/elutia-inc-nasdaq-elut-pioneering-drug-eluting-biomatrices-to-revolutionize-implantable-device-outcomes
0 · Reply
Fibopapi
Fibopapi Mar. 26 at 2:06 AM
$ELUT on watch for tomorrow
0 · Reply
fastmoneytraders
fastmoneytraders Mar. 25 at 9:42 PM
shorted $ELUT top ticked it 4.0801 cov 3.23
0 · Reply
BobbyH1
BobbyH1 Mar. 18 at 7:49 PM
$ELUT Showing a lot of strength in a very red market the last week. Good sign.
0 · Reply
BobbyH1
BobbyH1 Mar. 12 at 8:52 PM
$ELUT Any thoughts after the call? This one seems like a promising lottery ticket, super low float with potentially market leader in their new product. If it continues to gain traction, this could escalate rapidly. Also a buyout candidate if the product really starts to gain significant market share.
1 · Reply
Greenpa
Greenpa Mar. 11 at 3:25 PM
$ELUT Will be changing name to Dilutia.
0 · Reply
JarvisFlow
JarvisFlow Mar. 7 at 4:16 PM
Cantor Fitzgerald updates rating for Elutia ( $ELUT ) to Overweight, target set at 8.
0 · Reply
Greenpa
Greenpa Mar. 4 at 5:37 PM
$ELUT Hopefully management can address in the call or an analyst can ask what is being done to get litigation resolved and litigation costs under control. I know management can’t say a lot but this seems like a bet the company sort of litigation matter that warrants some general candid discussion of scope of possible outcomes. Shareholders shouldn’t be kept in the dark.
0 · Reply
Greenpa
Greenpa Mar. 1 at 11:29 PM
$ELUT I should add that they have increased book reserve to $25M — up from about $15M. I was leaning toward buying small position. CEO and board look to me like they are betting an awful lot on this. They should be openly acknowledging and discussing exposure as I sense they are maybe betting the company. I have not bothered to look for any public filings but when you have this big a liability there should be transparency. It may account for the $2.50 offer price and the pathetic trading volume.
0 · Reply
Greenpa
Greenpa Mar. 1 at 5:38 PM
$ELUT So it looks like company is burying bad news and cash burn in footnotes. Q3 PR states “the Company defines adjusted EBITDA as EBITDA excluding income from discontinued operations, stock-based compensation, FiberCel litigation costs”. So toxic is treated as discontinued operations. Burning over $10M annually just in litigation costs!!!
0 · Reply
Greenpa
Greenpa Feb. 26 at 5:34 PM
$ELUT struggling with how investors are comfortable with sizable litigation liability. More of a question than a statement at this point in my so far limited due diligence.
0 · Reply